Reach Us +1 218 451 2974
Dendrimer′s-New Hope In The Treatment Of Alzheimer′s Disease | 57419
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Dendrimer′s-New hope in the treatment of Alzheimer′s disease

5th International Conference on Alzheimer’s Disease & Dementia

Jerzy Leszek

Wroclaw Medical University, Poland

Keynote: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460.C1.020

The lack of effective treatment for Alzheimer’s disease(AD) stems mainly from the incomplete understanding of AD causes. Currently there are several hypotheses which try to explain the early molecular mechanisms of AD pathogenesis. Nanomedicine as a biomedical and pharmaceutical application of nanotechnology for making nanocarriers like dendrimers has shown great potential for the treatment of many CNS diseases. Dendrimers are polymeric molecules chemically synthesized with well defined shape size and nanoscopic physicochemical properties reminiscent of proteins. Recently an increasing number of studies have been focused on the potential of dendrimers to prevent aggregation and fibrillation of proteins involved in neurodegenerative disorders such as AD. Some of dendrimers were demonstrated to cross blood-brain barrier, which legitimized research on these compounds as potential drugs for neurological disorders. Recent our studies have revealed that dendrimers possess the intrinsic ability to localize in cells associated with neuroinflammation(activated microglia and astrocytes) and thus can be used as drug carriers in neuroinflammation therapy. Above/mentioned findings may be of high significance in the context of potential application of dendrimers as drug carriers or active compounds per se. According to the opinion the author’s of this presentation ,they are promising macromolecules for further investigations on their applicable in neurodegenerative disorders , for instance AD.

Jerzy Leszek is Professor of Psychiatry, Vice-Head of the Department of Psychiatry and Head of Alzheimer’s Disease Lab at the Medical University in Wroclaw, Poland. He graduated at Medical University of Wroclaw in 1979, was awarded a doctorate in Wroclaw in 1981 and in 1999- examination for the degree of associate professor of psychiatry and since 2007 he is working as full professor of psychiatry at Wroclaw Medical University. He is author and co-author more than 280 papers (especially from old age psychiatry), some chapters to the books published in reputed Polish and international journals and serving as an editorial board member of several journals.

Email: [email protected]

Relevant Topics